![“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/70a5f0fed7009863fe30cf0740cf32014ebaf5be-2974x1660.png?w=350&fit=crop&auto=format)
“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.
Barry Paul, MD
Advertisement
Articles by Barry Paul, MD
Barry Paul, MD, listed cilta-cel, anito-cel, and arlo-cel as 3 of the CAR T-cell therapies with the most promising efficacy in patients with multiple myeloma.
Advertisement
Latest Updated Articles
![“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/70a5f0fed7009863fe30cf0740cf32014ebaf5be-2974x1660.png?w=300&fit=crop&auto=format)
Addressing the Future of CAR T-Cell Therapies in Multiple MyelomaPublished: August 10th 2025 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Imlunestrant in ER+/HER2– ESR1+ Breast Cancer
2
Carotuximab/Apalutamide Improves PFS in Previously Treated Metastatic CRPC
3
The FDA Grants Priority Review to T-DXd/Pertuzumab in 1L Metastatic Breast Cancer
4
The COCOON Study Design and Baseline Characteristics
5
